CXCL1 and neoplasm: Mechanistic investigations revealed that UCA binds to IκBα in tumor endothelial cells, thereby inhibiting the NF-κB–CXCL1 signaling pathway, reducing myeloid-derived suppressor cell (MDSC) infiltration, improving the immune microenvironment, and enhancing the efficacy of anti-PD-1 therapy.